• Aurora A in Retinoblastoma: Evidence for Targeting

  2026-09-12

  The reference study identifies Aurora kinase A as a frequently elevated and clinically relevant vulnerability in human retinoblastoma. By integrating patient-specimen immunohistochemistry with genetic, pharmacologic, cell-based, and xenograft experiments, it links AURKA expression to high-risk histopathology and MYCN-associated tumor biology.

• miR-18a, ALOXE3, and Ferroptosis in GBM

  2026-09-12

  The reference study identifies a miR-18a/ALOXE3 axis that connects altered lipid metabolism with ferroptosis resistance and glioblastoma migration. Its combination of molecular, lipid-mediator, cellular, and orthotopic-model evidence positions ALOXE3 loss as a functional driver of tumor progression rather than simply a disease-associated expression change.

• Mouse Neutrophil Cell Isolation Kit for Immunotherapy

  2026-09-11

  Build fast, activation-conscious neutrophil workflows from mouse bone marrow, blood, or spleen for functional immunology and tumor studies. Negative selection preserves the target cells for assays involving biomimetic mRNA nanovaccines, cytokine responses, co-culture, and immune profiling.

• 2X Taq PCR Master Mix for CRC Genotyping

  2026-09-11

  A practical guide to applying 2X Taq PCR Master Mix in colorectal cancer genotyping, amplicon verification, and TA cloning workflows. Integrated loading dye and adenine-overhang chemistry reduce handling steps while preserving clear boundaries around endpoint PCR, sequencing, and expression analysis.

• NETs in CML: Differential Effects of TKIs

  2026-09-10

  Telerman and colleagues show that neutrophil extracellular trap formation is elevated in treatment-naïve chronic myeloid leukemia and is differentially altered by tyrosine kinase inhibitors. The study combines patient-derived neutrophils with a BCR-ABL1-engineered neutrophil model, providing a mechanistic framework for investigating how leukemia biology and TKI exposure may intersect with vascular risk.

• From Glycan Biology to PCR-Ready Translational Evidence

  2026-09-10

  The biology of MYCN-amplified neuroblastoma is revealing a connection between oncogenic transcription, GDP-fucose metabolism, and core fucosylation. This thought-leadership article explains how a routine PCR workflow can support mechanistic validation, model characterization, and translational assay development without overstating what endpoint amplification can prove.

• Vitamin C in Organoid Cancer and HEV Research

  2026-09-09

  Explore how Vitamin C (ascorbic acid) can be positioned as a controlled assay variable in cancer models and emerging HEV organoid systems. This evidence-led guide connects dose-dependent tumor phenotypes with practical controls for interpreting antiviral and host-response data.

• Bile Acid Retention and Immune Escape in MASH-HCC

  2026-09-09

  A 2026 Cancer Letters study identifies a GPR120–FXR–ABCB11–bile acid–NLRC5 axis that links lipid-associated metabolic stress to defective MHC-I antigen presentation in MASH-HCC. The findings provide a mechanistic rationale for combining bile acid pathway correction with anti-PD-1 therapy, while also defining important boundaries for translating the work into cytokine and antigen-presentation assays.

• 2X Taq PCR Master Mix for CAdV-2 Assays

  2026-09-08

  Learn how 2X Taq PCR Master Mix supports variant-aware CAdV-2 genotyping, gel-based amplicon analysis, and TA cloning. This article connects a recent canine adenovirus pathogenicity study with practical assay design, interpretation, and workflow controls.

• MG-132 Workflow for Proteasome and Apoptosis Studies

  2026-09-07

  MG-132, also known as Z-LLL-al, gives researchers temporal control over proteasome-dependent protein accumulation, apoptosis, oxidative stress, and cell-cycle responses. This practical guide connects dose-finding and orthogonal readouts with a heterochromatin study, helping investigators distinguish proteasome biology from downstream stress or off-target effects.

• Viral RIPK3 Degradation and Necroptotic Inflammation

  2026-09-07

  Liu et al. show that orthopoxviruses can encode a viral inducer of RIPK3 degradation, or vIRD, that hijacks SCF ubiquitin-ligase machinery to suppress necroptosis. The study connects this immune-evasion mechanism with viral replication, inflammation, and host susceptibility, while providing a framework for experimentally separating RIPK3-dependent effects from broader ubiquitin-pathway perturbations.

• PRMT5-Driven Splicing Vulnerability in MYCN Neuroblastoma

  2026-09-05

  Bojko and colleagues show that MYCN-amplified neuroblastoma depends on PRMT5-regulated RNA splicing, epitranscriptomic control, and glutamine metabolism. Their integrated transcriptomic, isotope-tracing, protein, and mouse studies connect spliceosomal disruption to reduced GLS abundance and impaired nutrient sensing, providing a mechanistic framework for metabolic vulnerability studies.

• CD28–ARS2 Drives CD8+ T-Cell Metabolic Flexibility

  2026-09-05

  The 2024 reference study identifies a CD28–ARS2 signaling axis that reshapes alternative splicing in mature CD8+ T cells, favoring PKM2 over PKM1 and supporting flexible glucose use, interferon-γ production, and antitumor activity. Its main contribution is to show that costimulation can reprogram T-cell metabolism through RNA processing independently of the canonical CD28–PI3K pathway, suggesting a framework for pairing splicing, metabolic, and functional measurements.

• hiPSC Intestinal Organoids for Pharmacokinetics

  2026-09-04

  Saito and colleagues developed an accessible direct three-dimensional culture workflow for generating intestinal organoids from human induced pluripotent stem cells. The resulting organoids could be expanded, cryopreserved, and converted into intestinal epithelial monolayers containing metabolically and transport-competent enterocytes for pharmacokinetic studies.

• Estradiol Benzoate: ERα Assay Workflow

  2026-09-04

  Build more reproducible estrogen receptor experiments with a practical workflow for stock preparation, ERα binding, and downstream signaling readouts. This guide also shows how structure-based screening concepts can inform assay prioritization without overstating evidence from unrelated antiviral research.

8432 records 1/563 page Next 12345 下5页 Last page